Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Managed Care & Specialty Pharmacy|November 1, 2022
Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United StatesLia N Pizzicato, Aisha Vadhariya, Julie Birt, et al.
Circulation|February 6, 2014
Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarctionSuzanne V Arnold, Mikhail Kosiborod, Fengming Tang, et al.
ACR Open Rheumatology|May 5, 2024
Real-World Treatment Patterns, Clinical Outcomes, and Symptom Burden in Patients With Psoriatic Arthritis Prescribed Ixekizumab in the United StatesSherry Rohekar, Aisha Vadhariya, Sarah Ross, et al.
Arthritis Research & Therapy|February 11, 2021
Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPowerW Benjamin Nowell, Kelly Gavigan, Carol L Kannowski, et al.
Rheumatology and Therapy|January 6, 2022
Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 TrialsDalton Sholter, Jianmin Wu, Bochao Jia, et al.
Clinical Rheumatology|June 7, 2022
Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USATheresa Hunter, Michael Grabner, Julie Birt, et al.
Advances in Therapy|March 5, 2024
Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of IxekizumabSanjay Chabra, Julie Birt, Rebecca Bolce, et al.
Clinical and Experimental Rheumatology|December 18, 2018
Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeksArthur Kavanaugh, Helena Marzo-Ortega, Ronald Vender, et al.
Annals of the Rheumatic Diseases|May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studiesArthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Drugs - Real World Outcomes|June 24, 2024
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis RegistryMark Lebwohl, Bruce Strober, Amy Schrader, et al.
Pageof 4